BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang J, Zhang C, He W, Gou X. Effect of m6A RNA Methylation Regulators on Malignant Progression and Prognosis in Renal Clear Cell Carcinoma. Front Oncol 2020;10:3. [PMID: 32038982 DOI: 10.3389/fonc.2020.00003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Nombela P, Miguel-López B, Blanco S. The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer 2021;20:18. [PMID: 33461542 DOI: 10.1186/s12943-020-01263-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
2 Chen Y, Wang S, Cho WC, Zhou X, Zhang Z. Prognostic Implication of the m6A RNA Methylation Regulators in Rectal Cancer. Front Genet 2021;12:604229. [PMID: 34149792 DOI: 10.3389/fgene.2021.604229] [Reference Citation Analysis]
3 Zhu D, Liu Y, Chen J, Wang Q, Li Y, Zhu Y, Feng J, Jiang J. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03496-3] [Reference Citation Analysis]
4 Liu T, Wang H, Fu Z, Wang Z, Wang J, Gan X, Wang A, Wang L. Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1. Cancer Sci 2021. [PMID: 34813676 DOI: 10.1111/cas.15212] [Reference Citation Analysis]
5 Xu W, Tian X, Liu W, Anwaier A, Su J, Zhu W, Wan F, Shi G, Wei G, Qu Y, Zhang H, Ye D. m6A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:709579. [PMID: 34295828 DOI: 10.3389/fonc.2021.709579] [Reference Citation Analysis]
6 Bai Z, Wang X, Zhang Z. Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma. Front Genet 2022;13:655169. [DOI: 10.3389/fgene.2022.655169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yang F, Zhao G, Ge L, Song Y, Hong K, Zhang H, Liu C, Hong P, Ma L. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis. Biomed Res Int 2021;2021:4582082. [PMID: 33628782 DOI: 10.1155/2021/4582082] [Reference Citation Analysis]
8 Xie Z, Wu L, Hua S, Zhang Y, Shi F, Chen M, Zhao S, Liu Z, Liu M, Jiang J. External Validation of the Prognostic Value of an Immune-Associated Gene Panel for Clear Cell Renal Cell Carcinomas. Front Cell Dev Biol 2021;9:794840. [PMID: 35004689 DOI: 10.3389/fcell.2021.794840] [Reference Citation Analysis]
9 Li H, Hu J, Yu A, Othmane B, Guo T, Liu J, Cheng C, Chen J, Zu X. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Front Oncol 2021;11:642159. [PMID: 33816290 DOI: 10.3389/fonc.2021.642159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang QX, Yang Y, Yang H, Guo Q, Guo JL, Liu HS, Zhang J, Li D. The roles of risk model based on the 3-XRCC genes in lung adenocarcinoma progression. Transl Cancer Res 2021;10:4413-31. [PMID: 35116299 DOI: 10.21037/tcr-21-1431] [Reference Citation Analysis]
11 Wang W, Shen C, Zhao Y, Sun B, Qiu X, Yin S, Chen J, Li X. The Role of m6A RNA Methylation-Related lncRNAs in the Prognosis and Tumor Immune Microenvironment of Papillary Thyroid Carcinoma. Front Cell Dev Biol 2021;9:719820. [PMID: 35047491 DOI: 10.3389/fcell.2021.719820] [Reference Citation Analysis]
12 Lin S, Xu H, Zhang A, Ni Y, Xu Y, Meng T, Wang M, Lou M. Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma. Front Oncol 2020;10:541401. [PMID: 33123464 DOI: 10.3389/fonc.2020.541401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
13 Na Z, Fan L, Wang X. Gene Signatures and Prognostic Values of N6-Methyladenosine Related Genes in Ovarian Cancer. Front Genet 2021;12:542457. [PMID: 34484284 DOI: 10.3389/fgene.2021.542457] [Reference Citation Analysis]
14 Xiao K, Zhao S, Yuan J, Pan Y, Song Y, Tang L. Construction of Molecular Subtypes and Related Prognostic and Immune Response Models Based on M2 Macrophages in Glioblastoma. IJGM 2022;Volume 15:913-26. [DOI: 10.2147/ijgm.s343152] [Reference Citation Analysis]
15 von Hagen F, Gundert L, Strick A, Klümper N, Schmidt D, Kristiansen G, Tolkach Y, Toma M, Ritter M, Ellinger J. N6 -Methyladenosine (m6 A) readers are dysregulated in renal cell carcinoma. Mol Carcinog 2021;60:354-62. [PMID: 33755994 DOI: 10.1002/mc.23297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Huang W, Chen TQ, Fang K, Zeng ZC, Ye H, Chen YQ. N6-methyladenosine methyltransferases: functions, regulation, and clinical potential. J Hematol Oncol 2021;14:117. [PMID: 34315512 DOI: 10.1186/s13045-021-01129-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Wu J, Hou C, Wang Y, Wang Z, Li P, Wang Z. Comprehensive Analysis of m5C RNA Methylation Regulator Genes in Clear Cell Renal Cell Carcinoma. Int J Genomics 2021;2021:3803724. [PMID: 34631874 DOI: 10.1155/2021/3803724] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bian S, Ni W, Zhu M, Song Q, Zhang J, Ni R, Zheng W. Identification and Validation of the N6-Methyladenosine RNA Methylation Regulator YTHDF1 as a Novel Prognostic Marker and Potential Target for Hepatocellular Carcinoma. Front Mol Biosci 2020;7:604766. [PMID: 33363211 DOI: 10.3389/fmolb.2020.604766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
19 Deng M, Fang L, Li SH, Zhao RC, Mei J, Zou JW, Wei W, Guo RP. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma. Mutagenesis 2021;36:369-79. [PMID: 34467992 DOI: 10.1093/mutage/geab032] [Reference Citation Analysis]
20 Sang L, Sun L, Wang A, Zhang H, Yuan Y. The N6-Methyladenosine Features of mRNA and Aberrant Expression of m6A Modified Genes in Gastric Cancer and Their Potential Impact on the Risk and Prognosis. Front Genet 2020;11:561566. [PMID: 33329697 DOI: 10.3389/fgene.2020.561566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Li Y, Peng H, Jiang P, Zhang J, Zhao Y, Feng X, Pang C, Ren J, Zhang H, Bai W, Liu W. Downregulation of Methyltransferase-Like 14 Promotes Ovarian Cancer Cell Proliferation Through Stabilizing TROAP mRNA. Front Oncol 2022;12:824258. [DOI: 10.3389/fonc.2022.824258] [Reference Citation Analysis]
22 Miao Y, Su B, Tang X, Wang J, Quan W, Chen Y, Mi D. Construction and validation of m6 A RNA methylation regulators associated prognostic model for gastrointestinal cancer. IET Syst Biol 2022. [PMID: 35174637 DOI: 10.1049/syb2.12040] [Reference Citation Analysis]
23 Wu X, Sheng H, Wang L, Xia P, Wang Y, Yu L, Lv W, Hu J. A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients. Aging (Albany NY) 2021;13:10034-57. [PMID: 33795529 DOI: 10.18632/aging.202761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Huang W, Li G, Wang Z, Zhou L, Yin X, Yang T, Wang P, Teng X, Feng Y, Yu H. A Ten-N6-Methyladenosine (m6A)-Modified Gene Signature Based on a Risk Score System Predicts Patient Prognosis in Rectum Adenocarcinoma. Front Oncol 2020;10:567931. [PMID: 33680913 DOI: 10.3389/fonc.2020.567931] [Reference Citation Analysis]
25 Wang S, Zou X, Chen Y, Cho WC, Zhou X. Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer. Front Genet 2020;11:580036. [PMID: 33584787 DOI: 10.3389/fgene.2020.580036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhao J, Huang S, Tan D, Yang K, Chen M, Jia X, Mao X, Xu Y. PGM1 and ENO1 Promote the Malignant Progression of Bladder Cancer via Comprehensive Analysis of the m6A Signature and Tumor Immune Infiltration. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/8581805] [Reference Citation Analysis]
27 Cai Y, Feng R, Lu T, Chen X, Zhou X, Wang X. Novel insights into the m6A-RNA methyltransferase METTL3 in cancer. Biomark Res 2021;9:27. [PMID: 33879256 DOI: 10.1186/s40364-021-00278-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wang X, Xie H, Ying Y, Chen D, Li J. Roles of N6 -methyladenosine (m6 A) RNA modifications in urological cancers. J Cell Mol Med 2020;24:10302-10. [PMID: 32808488 DOI: 10.1111/jcmm.15750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]